Author

Itzcóatl A. Gómez

University College Dublin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Apostolos TsopanoglouiD· 2 shared Ioscani Jiménez del ValiD· 2 shared Jonathan BonesiD· 2 shared Mina GhahremanzamanehiD· 2 shared Sara CarilloiD· 2 shared Alfonso BlancoiD· 1 shared Brian GlennoniD· 1 shared Kallum DoyleiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Apostolos TsopanoglouORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringbioRxivPreprintSep 28, 2026

Next-gen glycoengineering: combining cellular and metabolic engineering to fine tune mAb β1,4-galactosylation

Apostolos Tsopanoglou, Mina Ghahremanzamaneh, Itzcóatl A. Gómez…·Ioscani Jiménez del Val

This paper combines metabolic and cellular glycoengineering to control mAb β1,4-galactosylation, achieving broad tunable control and improved pharmacological activity.

DOI 10.64898/2026.09.26.754714

experimental assay

𝕏 PostBluesky

BioengineeringMetabolic EngineeringPeer-reviewedSep 7, 2026

Computationally inspired glycoengineering to maximise mAb β4-galactosylation

Itzcóatl A. Gómez, Mina Ghahremanzamaneh, Apostolos Tsopanoglou…·Ioscani Jiménez del Val

This paper describes a dual genetic engineering strategy to enhance mAb β4-galactosylation in CHO cells, achieving over 90% galactosylation and reducing Man5 glycans without affecting mAb titre.

DOI 10.1016/j.ymben.2026.102549

mouseproteomics

𝕏 PostBluesky